UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group

The lancet oncology, 2016-10, Vol.17 (10), p.1453-1462

2016

Volltextzugriff (PDF)

Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience

Cancers, 2023-12, Vol.15 (24), p.5738

2023

Volltextzugriff (PDF)

Facial nerve paralysis caused by a T‐cell lymphoma

Clinical case reports, 2020-12, Vol.8 (12), p.2965-2968

2020

Volltextzugriff (PDF)

P008: Impact of bone marrow involvement on early PET response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

HemaSphere, 2022-10, Vol.6 (Suppl), p.4-4

2022

Volltextzugriff (PDF)

Comparing Revised Latent State-Trait Models Including Autoregressive Effects

Psychological methods, 2024-02, Vol.29 (1), p.155-168

2024

Volltextzugriff (PDF)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma

HemaSphere, 2022-10, Vol.6 (Suppl), p.17-18

2022

Volltextzugriff (PDF)

Tumorbedingte Fatigue bei Patienten mit Hodgkin-Lymphom

Forum (Heidelberg), 2016-09, Vol.31 (4), p.305-310

2016

Volltextzugriff (PDF)

Bewährte Strategien und neue Ansätze

Im Fokus Onkologie, 2015-02, Vol.18 (1-2), p.58-64

2015

Volltextzugriff (PDF)

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Journal of clinical oncology, 2017-06, Vol.35 (18), p.1999-2007

2017

Volltextzugriff (PDF)

Reduced‐Intensity Chemotherapy in Patients With Advanced‐Stage Hodgkin Lymphoma

HemaSphere, 2017-12, Vol.1 (1), p.1-9

2017

Volltextzugriff (PDF)

Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3528-3537

2019

Volltextzugriff (PDF)

The Interplay Between Cancer-Related Fatigue and Functional Health in Hodgkin Lymphoma Survivors

Health psychology, 2020-10, Vol.39 (10), p.905-911

2020

Volltextzugriff (PDF)

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

The lancet oncology, 2017-12, Vol.18 (12), p.1680-1687

2017

Volltextzugriff (PDF)

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study

Journal of clinical psychology in medical settings, 2023-12, Vol.30 (4), p.856-865

2023

Volltextzugriff (PDF)

Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

Journal of clinical oncology, 2020-09, Vol.38 (25), p.2839-2848

2020

Volltextzugriff (PDF)

Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration

Journal of clinical oncology, 2016-12, Vol.34 (36), p.4329-4337

2016

Volltextzugriff (PDF)

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group

Leukemia & lymphoma, 2019-05, Vol.60 (6), p.1389-1398

2019

Volltextzugriff (PDF)

Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

British journal of haematology, 2021-05, Vol.193 (3), p.515-519

2021

Volltextzugriff (PDF)

How I treat advanced Hodgkin lymphoma — a global view

British journal of haematology, 2020-09, Vol.190 (6), p.837-850

2020

Volltextzugriff (PDF)

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

The Lancet (British edition), 2024-07, Vol.404 (10450), p.341-352

2024

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Humans
(18)
Female
(15)
Male
(15)
Hematology
(13)
Lymphoma
(13)
Middle Aged
(12)
Oncology
(12)
Adult
(11)
Hodgkin Lymphoma
(10)
Hodgkin's Lymphoma
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Aged
(7)
Chemotherapy
(7)
Hodgkin Disease - Drug Therapy
(7)
Prognosis
(7)
Young Adult
(7)
Neoplasm Staging
(6)
Adolescent
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience

Facial nerve paralysis caused by a T‐cell lymphoma

P008: Impact of bone marrow involvement on early PET response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

Comparing Revised Latent State-Trait Models Including Autoregressive Effects

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Tumorbedingte Fatigue bei Patienten mit Hodgkin-Lymphom

Bewährte Strategien und neue Ansätze

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Reduced‐Intensity Chemotherapy in Patients With Advanced‐Stage Hodgkin Lymphoma

Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

The Interplay Between Cancer-Related Fatigue and Functional Health in Hodgkin Lymphoma Survivors

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study

Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

How I treat advanced Hodgkin lymphoma — a global view

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Suchergebnisse filtern